These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25102101)

  • 1. Is there a role for antimicrobial stewardship in cystic fibrosis?
    Waters VJ; Ratjen FA
    Ann Am Thorac Soc; 2014 Sep; 11(7):1116-9. PubMed ID: 25102101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G; Campana S; Festini F; Mascherini M; Döring G
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
    Steinkamp G
    Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of Pseudomonas aeruginosa in cystic fibrosis.
    Eber E; Thalhammer GH; Zach MS
    Eur Respir J; 2006 Feb; 27(2):438-9. PubMed ID: 16452606
    [No Abstract]   [Full Text] [Related]  

  • 7. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.
    Waters VJ; Kidd TJ; Canton R; Ekkelenkamp MB; Johansen HK; LiPuma JJ; Bell SC; Elborn JS; Flume PA; VanDevanter DR; Gilligan P;
    Clin Infect Dis; 2019 Oct; 69(10):1812-1816. PubMed ID: 31056660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
    Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
    Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa.
    Béghin L; Michaud L; Loeuille GA; Wizla-Derambure N; Sayah H; Sardet A; Thumerelle C; Deschildre A; Turck D; Gottrand F
    Pediatr Pulmonol; 2009 May; 44(5):464-71. PubMed ID: 19360849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection.
    Donnelly RF; McCarron PA; Cassidy CM; Elborn JS; Tunney MM
    J Control Release; 2007 Feb; 117(2):217-26. PubMed ID: 17196290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication therapy for early Pseudomonas aeruginosa infection in CF: many questions still unanswered.
    Jones AM
    Eur Respir J; 2005 Sep; 26(3):373-5. PubMed ID: 16135714
    [No Abstract]   [Full Text] [Related]  

  • 17. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
    Govan JR; Brown AR; Jones AM
    Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.